Marinus Announces Completion of Marigold Trial

Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder

“Enrolling 100 patients in our registrational, pivotal Phase 3 trial evaluating ganaxolone in children with CDD is a significant milestone for both Marinus and the CDD community,” said Joe Hulihan, M.D., Chief Medical Officer of Marinus. “Our ability to identify and rapidly enroll qualified patients into this study is indicative of the significant need for a new therapy to reduce seizure burden and improve patient outcomes. The study has been well conducted and we are encouraged by the limited adverse events, low dropout rates and the vast majority of patients entering the open-label extension. We are appreciative of the patients and broader CDD community for their participation in the Marigold study and we remain committed to addressing the unmet need of these patients who currently have no approved treatment options.”

Read More
2019 AES Thought Leader Theatre

Thought Leader Theatre

IFCR President, Karen Utley, joins Eisai host Kimberly Bottom for the 2019 AES Thought Leader Theatre at the 2019 American Epilepsy Society Meeting to talk about our organization and CDKL5 Deficiency.

Read more to watch the video!


Read More
CDKL5 Deficiency Receives ICD-10-CM code: G40.42

ICD-10-CM code for CDD Approved!

Together with the Loulou Foundation and the directors of the CDKL5 Centers of Excellence, we submitted a proposal for the creation of a new ICD-10-CM code for CDKL5 Deficiency Disorder (CDD) that was reviewed during the September 11 meeting and is currently receiving comments until November 8, 2019. It is a pleasure to announce that the application to create a new ICD-10-CM code for CDD: G40.42 Cyclin-Dependent Kinase-Like 5 Deficiency Disorder, CDKL5 was approved.

Read More
CDKL5 Forum 2019

The CDKL5 Forum is an annual “by-invite-only” event hosted by the Loulou Foundation to report on the progression of the CDKL5 Deficiency Disorder field. IFCR board members, Rick Upp and Amanda Jaksha, and Science Director, Heidi Grabenstatter, attended this event that includes scientists, industry representatives, clinicians, and nonprofit leaders invested specifically in CDKL5 Deficiency Disorder (CDD). It was clear that the rapid progress occurring in CDD research …

Read More
IFCR Launches Two New CDKL5 Centers of Excellence

The International Foundation for CDKL5 Research is proud to announce the launch of two new CDKL5 Centers of Excellence in the Children’s Hospital of Philadelphia and the University of California Mattel Children’s Hospital in Los Angeles. The Philadelphia CDLK5 Center of Excellence was made possible due to the generous support from the Lauren Mary Francis Foundation.

Read More
CDKL5 PFDD Webinar

Join us on Tuesday, August 6, at 8:00 pm ET for a webinar to learn more about our upcoming CDKL5 Deficiency Patient-Focused Drug Development (PFDD) meeting. On November 1, 2019, IFCR and the LouLou foundation will co-sponsor this externally-led meeting for CDD. This is a once-in-a-lifetime opportunity for caretakers to share the patient voice with a variety of stakeholders interested in developing treatments for CDD.

Read More
For Families
Get Involved